The Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting Poster, November 8, 2019 Preclinical Development of a Novel, Allogeneic, OX40L-Secreting, Therapeutic Cancer Vaccine for use in Combination with a gp96-Secreting Vaccine for Solid Tumors
The Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting Poster, November 8, 2019; Treating Advanced Non-Small Lung Cancer (NSCLC) Patients After Checkpoint Inhibitor Treatment Failure With a Novel Combination of Viagenpumatucel-L (HS-110) Plus Nivolumab
Gp96-Ig/costimulator (OX40L, ICOSL, or 4-1BBL) Combination Vaccine Improves T cell Priming and Enhances Immunity, Memory, and Tumor Elimination Heat Biologics 2017
